drugset / Trial / NCT00191620

Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

NCT00191620 ↗

Phase 2 Completed 64 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer. The safety of standard gemcitabine plus cisplatin and any side effects that might be associated with it as compared to a fixed dose rate of gemcitabine plus cisplatin.

Timeline

Start
2004-03
Primary completion
—
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Gemcitabine Small molecule 1000 mg/m2 —